36 research outputs found
Recommended from our members
National shortage of home intravenous inotrope agents: The “inotrope pandemic” continues
Recommended from our members
USE OF HEMOTAG™ CARDIOPULMONARY ASSESSMENT SYSTEM FOR PREDICTING CLINICAL DECOMPENSATION IN HEART FAILURE IN THE INPATIENT SETTING
Recommended from our members
BLOOD TRANSFUSION PRIOR TO HEART TRANSPLANTATION AND ITS ASSOCIATION TO GRAFT REJECTION: SINGLE CENTER EXPERIENCE
Recommended from our members
SPECTRUM OF HEART FAILURE PHENOTYPES AT THE TIME OF TRANSTHYRETIN CARDIAC AMYLOIDOSIS DIAGNOSIS; A SINGLE-CENTER EXPERIENCE
Recommended from our members
WORSENING RENAL FUNCTION IN PATIENTS WITH ATTR CARDIAC AMYLOIDOSIS DURING THE FIRST YEAR FOLLOWING DIAGNOSIS
Recommended from our members
UNEARTHING THE HIDDEN MENACE: STRONGYLOIDES STERCORALIS IN A POST-TRANSPLANT PATIENT
Recommended from our members
PREDICT HF: Risk stratification in advanced heart failure using novel hemodynamic parameters
Background: Invasive hemodynamics are fundamental in assessing patients with advanced heart failure (HF). Several novel hemodynamic parameters have been studied; however, the relative prognostic potential remains ill-defined. Hypothesis: Advanced hemodynamic parameters provide additional prognostication beyond the standard hemodynamic assessment. Methods: Patients from the PRognostic Evaluation During Invasive CaTheterization for Heart Failure (PREDICT-HF) registry who underwent right heart catheterization (RHC) were included in the analysis. The primary endpoint was survival to orthotopic heart transplant (OHT) or durable left ventricular assist device (LVAD), or death within 6 months of RHC. Results: Of 846 patients included, 176 (21%) met the primary endpoint. In a multivariate model that included traditional hemodynamic variables, pulmonary capillary wedge pressure (PCWP) (OR: 1.10, 1.04-1.15, p Conclusion: The advanced hemodynamic parameters API and CPO are independently associated with death or the need for OHT or LVAD within 6 months. Further prospective studies are needed to validate these parameters and elucidate their role in patients with advanced HF.</p